Education
About Us
Working with TipRanks
Follow Us
Lexeo Therapeutics, Inc. (LXEO)
NASDAQ:LXEO
LXEO Stock Chart & Stats
$7.57
-$0.29(-4.02%)
At close: 4:00 PM EST
$7.57
-$0.29(-4.02%)
Day’s Range― - ―
52-Week Range$1.45 - $10.99
Previous CloseN/A
Volume22.32K
Average Volume (3M)1.44M
Market Cap
$543.03M
Enterprise Value$519.98M
Total Cash (Recent Filing)$41.00M
Total Debt (Recent Filing)$8.46M
Price to Earnings (P/E)―
Beta2.02
Next Earnings
Mar 16, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.33
Shares Outstanding72,987,330
10 Day Avg. Volume813,978
30 Day Avg. Volume1,439,523
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)1.79
Price to Sales (P/S)0.00
P/FCF Ratio-2.56
Enterprise Value/Market Cap0.96
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-337.43
Enterprise Value/Ebitda-5.06
Forecast
1Y Price Target
$18.20Price Target Upside140.42% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
EPS Forecast (FY)-1.52
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Biomarker Target EngagementBiopsy results showing increased PKP2 protein indicate the therapy engages its intended target, supporting biological activity and strengthening confidence in the program's mechanism.
Regulatory Pathway ClarityFDA feedback that allows pooling of Phase 1/2 and pivotal data, contingent on manufacturing comparability and modest nonclinical work, creates a clearer regulatory pathway for approval strategy.
Strategic Partnership CredibilityAnalyst's recommendation to buy is grounded in a collaboration with Johnson & Johnson that adds scientific and commercial credibility to the cardiac gene therapy platform.
Bears Say
Emerging Safety ConcernsA reported supraventricular tachycardia event and the risk of new or worsening safety signals could weaken the investment thesis and push valuation toward the company's existing assets.
Inconsistent Clinical EfficacyPrimary arrhythmia measures have not reliably improved in the same patients who show reductions in premature ventricular contractions, raising doubts about consistent, multi-metric clinical benefit.
Medication ConfoundingBackground use or changes in anti-arrhythmic medications can create apparent efficacy in small cohorts, making it difficult to isolate true drug effect without normalizing for medication changes.
Lexeo Therapeutics, Inc. News
LXEO FAQ
What was Lexeo Therapeutics, Inc.’s price range in the past 12 months?
Lexeo Therapeutics, Inc. lowest stock price was $1.45 and its highest was $10.99 in the past 12 months.
What is Lexeo Therapeutics, Inc.’s market cap?
Lexeo Therapeutics, Inc.’s market cap is $543.03M.
When is Lexeo Therapeutics, Inc.’s upcoming earnings report date?
Lexeo Therapeutics, Inc.’s upcoming earnings report date is Mar 16, 2026 which is in 44 days.
How were Lexeo Therapeutics, Inc.’s earnings last quarter?
Lexeo Therapeutics, Inc. released its earnings results on Nov 05, 2025. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.19.
Is Lexeo Therapeutics, Inc. overvalued?
According to Wall Street analysts Lexeo Therapeutics, Inc.’s price is currently Undervalued.
Does Lexeo Therapeutics, Inc. pay dividends?
Lexeo Therapeutics, Inc. does not currently pay dividends.
What is Lexeo Therapeutics, Inc.’s EPS estimate?
Lexeo Therapeutics, Inc.’s EPS estimate is -0.32.
How many shares outstanding does Lexeo Therapeutics, Inc. have?
Lexeo Therapeutics, Inc. has 72,987,330 shares outstanding.
What happened to Lexeo Therapeutics, Inc.’s price movement after its last earnings report?
Lexeo Therapeutics, Inc. reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went down -1.796%.
Which hedge fund is a major shareholder of Lexeo Therapeutics, Inc.?
Currently, no hedge funds are holding shares in LXEO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Lexeo Therapeutics, Inc. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.20 (140.42% Upside)
$18.20 (140.42% Upside)
Blogger Sentiment
Bullish
LXEO Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $31.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 2.0%
Last 30 Days ▼ 2.8%
Last 30 Days ▼ 2.8%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
30.98%
12-Months-Change
Fundamentals
Return on Equity
-80.69%
Trailing 12-Months
Asset Growth
-17.27%
Trailing 12-Months
Company Description
Lexeo Therapeutics, Inc.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
LXEO Stock 12 Month Forecast
Average Price Target
$18.20
▲(140.42% Upside)
Technical Analysis
Tvardi Therapeutics
―
Larimar Therapeutics
―
Capricor Therapeutics
―
Benitec Biopharma
―
Diamedica Therapeutics
―
Ownership Overview
0.86% Insiders
5.40% Mutual Funds
25.26% Other Institutional Investors
55.56% Public Companies and
Individual Investors